FI955154A0 - Viruskombinantteja ja niiden käyttö geeniterapiassa - Google Patents

Viruskombinantteja ja niiden käyttö geeniterapiassa

Info

Publication number
FI955154A0
FI955154A0 FI955154A FI955154A FI955154A0 FI 955154 A0 FI955154 A0 FI 955154A0 FI 955154 A FI955154 A FI 955154A FI 955154 A FI955154 A FI 955154A FI 955154 A0 FI955154 A0 FI 955154A0
Authority
FI
Finland
Prior art keywords
pct
gene therapy
sec
date
viral
Prior art date
Application number
FI955154A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955154A (fi
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Sandrine Seguret
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI955154A0 publication Critical patent/FI955154A0/fi
Publication of FI955154A publication Critical patent/FI955154A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI955154A 1993-04-30 1995-10-27 Viruskombinantteja ja niiden käyttö geeniterapiassa FI955154A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9305125A FR2704556B1 (fr) 1993-04-30 1993-04-30 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000422 WO1994025073A1 (fr) 1993-04-30 1994-04-15 Virus recombinants et leur utilisation en therapie genique

Publications (2)

Publication Number Publication Date
FI955154A0 true FI955154A0 (fi) 1995-10-27
FI955154A FI955154A (fi) 1995-10-27

Family

ID=9446605

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955154A FI955154A (fi) 1993-04-30 1995-10-27 Viruskombinantteja ja niiden käyttö geeniterapiassa

Country Status (17)

Country Link
US (2) USRE38556E1 (es)
EP (1) EP0701450B1 (es)
JP (1) JPH08509373A (es)
KR (1) KR100330142B1 (es)
AT (1) ATE169503T1 (es)
AU (1) AU696199B2 (es)
BR (1) BR9406689A (es)
CA (1) CA2161679A1 (es)
DE (1) DE69412486T2 (es)
DK (1) DK0701450T3 (es)
ES (1) ES2120036T3 (es)
FI (1) FI955154A (es)
FR (1) FR2704556B1 (es)
GR (1) GR3027660T3 (es)
NO (1) NO954286L (es)
WO (1) WO1994025073A1 (es)
ZA (1) ZA942980B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
FR2731229B1 (fr) * 1995-03-02 1997-04-30 Rhone Poulenc Rorer Sa Therapie genique de l'atherosclerose par production de hdl par les lignees monocytaires
US5734699A (en) * 1995-05-04 1998-03-31 Interwave Communications International, Ltd. Cellular private branch exchanges
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
CZ326896A3 (cs) * 1996-11-07 1998-05-13 Milo Olomouc, A. S. Tuk se specifickými protisklerotickými účinky
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
BR9713847A (pt) 1996-12-06 2000-02-29 Rhone Poulenc Rorer Pharma Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico.
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CN1268641C (zh) * 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
US7227014B2 (en) * 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
JP4550421B2 (ja) * 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
EP1716165A4 (en) * 2004-01-23 2008-06-18 Virxsys Corp EXPRESSION OF APOLIPROTEIN A1 (APOA-1) AND VARIANTS USING SPLICE COMPLEX-INDUCED RNA TRANSPLANT
CN101189339A (zh) * 2005-03-22 2008-05-28 美得思达健康有限公司 诊断和治疗心血管疾病的递送系统和方法
WO2008040792A2 (en) * 2006-10-04 2008-04-10 Centre National De La Recherche Scientifique (Cnrs) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61135587A (ja) * 1984-12-03 1986-06-23 Norin Suisansyo Shokuhin Sogo Kenkyusho アポリポタン白質ｅ遺伝子およびその調製法
AU580145B2 (en) * 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
JPS63237795A (ja) * 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc アポリポタンパク質の製造法
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
FR2666813A1 (fr) * 1990-09-18 1992-03-20 Rhone Poulenc Sante Procede microbiologique de preparation de l'apolipoproteine aiv humaine ou de derives de celle-ci.
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
ATE237694T1 (de) * 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6777977B1 (en) * 2002-05-01 2004-08-17 Actel Corporation Three input field programmable gate array logic circuit configurable as a three input look up table, a D-latch or a D flip-flop
CA2419216C (en) * 2003-02-19 2005-03-01 Jan Nyquist Method and apparatus for joining plastic pipe

Also Published As

Publication number Publication date
DK0701450T3 (da) 1999-02-08
USRE38556E1 (en) 2004-07-13
CA2161679A1 (fr) 1994-11-10
WO1994025073A1 (fr) 1994-11-10
NO954286D0 (no) 1995-10-26
FR2704556B1 (fr) 1995-07-13
FR2704556A1 (fr) 1994-11-04
DE69412486D1 (de) 1998-09-17
GR3027660T3 (en) 1998-11-30
BR9406689A (pt) 1996-01-30
ES2120036T3 (es) 1998-10-16
AU696199B2 (en) 1998-09-03
AU6572294A (en) 1994-11-21
JPH08509373A (ja) 1996-10-08
EP0701450A1 (fr) 1996-03-20
DE69412486T2 (de) 1999-03-11
KR100330142B1 (ko) 2002-09-27
US5866551A (en) 1999-02-02
NO954286L (no) 1995-10-26
ZA942980B (en) 1995-01-18
EP0701450B1 (fr) 1998-08-12
ATE169503T1 (de) 1998-08-15
FI955154A (fi) 1995-10-27

Similar Documents

Publication Publication Date Title
FI955154A0 (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
FI955552A (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ZA943744B (en) Therapeutic substituted guanidines
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
EP0609280A4 (en) Human il-3 variants.
AU3352495A (en) Agents for inducing apoptosis and applications of said agents in therapy
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
GR3034142T3 (en) Composition for the treatment or prevention of herpes
NO960325L (no) Tryptaseinhibitor
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
MA Patent expired